Orexigen obesity drug meets goals in three studies

Monday, July 20, 2009

SAN DIEGO -- Orexigen Therapeutics Inc. said today that its obesity-drug candidate Contrave met its main goals in three late-stage clinical trials, and also surpassed a Food and Drug Administration requirement for effectiveness.

To continue reading
For more than 115 years, the Southeast Missourian has written the first draft of local history. We have aspired to enrich, entertain, educate and inform. Our core values have remained firm: truth, service, quality, integrity and community. Support our mission.